The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease

BMC Nephrology

Table 2 Predicted value of optimal serum potassium management to enable ongoing RAASi therapy in CKD patients

Discounting	Outcome	Treatment arm (ongoing RAASi)	Control arm (no RAASi)	Incremental benefit	Incremental NMB
Discounting	Outcome	Treatment arm (ongoing RAASi)	Control arm (no RAASi)	Incremental benefit	WTP at £20,000 per QALY	WTP at £30,000 per QALY
Undiscounted	Cost	£108,685	£108,720	-£35	£28,570	£42,837
	QALY	8.60	7.17	1.43
	LY	15.12	12.75	2.36
Discounted	Cost	£72,067	£75,202	-£3135	£23,446	£33,601
	QALY	6.68	5.67	1.02
	LY	11.32	9.77	1.56

CKD chronic kidney disease, ESRD end stage renal disease, LY life-year, NMB net monetary benefit, QALY quality-adjusted life-year, RAASi renin-angiotensin-aldosterone system inhibitor, WTP willingness-to-pay threshold
Simulated patients were aged 60 years at baseline, with CKD stage 3a (eGFR 52.5 mL/min/1.73m²) and serum potassium of 4.5 mEq/L; analyses were conducted independent of costs and utilities related to pharmacological potassium management

ISSN: 1471-2369